In addition to previous molecular studies on the enhanced expression of IMPDH2 [78,79,80], HNRNPK [81], OXCT1 [52], ACPP [39,40,41], LDHB [82], TUFM [42,43], HNRNPH3 [83], and CCT2 ([84,85,86], dysregulated expression of those proteins may be useful for clinicopathological features of prostate cancer patients. This evidence concerns the gene CCT2 and prostate carcinoma.